The Study
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
This study looked at many big experiments where people with diabetes were randomly given either the medicine or a fake pill. It found that the medicine helped lower the chance of heart attacks and kidney problems. But it doesn’t prove the medicine fixes diabetes or works the same for everyone.
Analysis score
Maximum 100 for a systematic review with meta-analysis.
Where the score came from
This study looked at 8 big trials to see if a type of diabetes medicine (GLP-1RA) helps protect the heart and kidneys.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 554 / 100
Quality score
The highest quality evidence. Systematic reviews and meta-analyses that pool randomized controlled trials, giving the most reliable summary of experimental evidence.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These reductions mean for every 100 people with diabetes taking this medicine, about 1 to 2 fewer will have a major heart problem or die over several years.
- 2It lowered heart attacks/strokes by 14%, heart failure hospitalizations by 10%, death from any cause by 12%, and kidney damage (macroalbuminuria) by 26%.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Cardiovascular Diabetology
Year
2021
Authors
D. Giugliano, L. Scappaticcio, M. Longo, P. Caruso, M. Maiorino, G. Bellastella, A. Ceriello, P. Chiodini, K. Esposito
Related Content
Claims (7)
GLP-1 drugs have different effects on heart health in different people.
In adults with type 2 diabetes, GLP-1 receptor agonists lower the rate of severe kidney protein loss by 26% and reduce the combined risk of kidney-related complications by 17%.
In adults with type 2 diabetes, GLP-1 receptor agonists are associated with a 13% lower risk of death from cardiovascular causes compared to those not receiving these drugs, as observed across multiple clinical trials.
In adults with type 2 diabetes, GLP-1 receptor agonists lower the rate of heart attacks, strokes, and cardiovascular deaths by 14% compared to no such treatment, as observed across multiple clinical trials.
In adults with type 2 diabetes, GLP-1 receptor agonists are associated with a 10% lower rate of hospitalization for heart failure compared to those not receiving these drugs.
In adults with type 2 diabetes, treatment with GLP-1 receptor agonists is associated with a 12% lower rate of death from any cause compared to those not receiving this treatment.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.